Bridging the gap between the laboratory bench and the patient’s bedside, the Holman Pathway supports a select group of residents committed to a career in academic medicine and scientific discovery. This specialized training track fosters innovation by allowing residents to pursue high-impact research alongside world-class mentors during their clinical training. We are proud to feature the work of our current trainees, whose diverse projects span the fields of cancer metabolism, hematopoiesis, computational oncology, and cardio-immunology. Their dedication to uncovering the mechanisms of disease ensures that the next generation of oncologic breakthroughs is already in motion.
Kevin Boehm, MD, PhD
Kevin Boehm, MD, PhD, is a Resident Physician and Research Fellow in the Holman Pathway, specializing in multimodal machine learning. His work focuses on bridging the gap between digital pathology and genomic sequencing for cancer diagnostics and biomarker discovery. Under the mentorship of Nikolaus Schultz, PhD, Francisco Sanchez-Vega, PhD, and Sohrab Shah, PhD in Computational Oncology, Dr. Boehm is developing computational models that integrate MSK-IMPACT (clinical panel sequencing) with pathology whole-slide images. By leveraging machine learning, his research identifies tumor phenotypes and molecular features that are predictive of response to therapy. Dr. Boehm has received funding from the Fund for Innovation in Cancer Informatics and the Artificial Intelligence Technology Development Investment Fund, is a member of the MSK Entrepreneurship Initiative, and has presented his AI research at major international summits in Montreal, Berlin, and Milan.
Alexander Goglia, MD, PhD
Alexander Goglia, MD, PhD, is a Resident Physician and Research Fellow in the Holman Pathway, specializing in the intersection of radiation oncology, hematology, and cancer evolution. His research focuses on therapy-related clonal hematopoiesis, a premalignant blood condition that can arise when cancer treatments like chemotherapy and radiation therapy inadvertently promote the growth of mutant blood stem cells. Working under the mentorship of Dr. Ross Levine, Dr. Goglia employs sophisticated genetic mouse models, large-scale CRISPR screens, and multi-omic profiling to identify the mechanisms by which specific mutations allow these cells to expand after cancer therapies. A recognized leader in his cohort, Dr. Goglia has been invited to present his work at major international conferences and has published widely in journals like Blood Advances, Journal of the National Cancer Institute, and JAMA Oncology. He is currently training to become an independent principal investigator and physician-scientist, dedicated to understanding early cancer evolution and to developing “interception” strategies that protect patients from the long-term side effects of life-saving cancer therapies.
Yuzhong (Jeff) Meng, MD, PhD
Jeff Meng, MD, PhD, is a Resident Physician in the Holman Pathway. His research investigates the clinical significance of the thymus as a potential “organ at risk” in radiation therapy, exploring how incidental dose to this primary lymphoid organ may influence long-term patient outcomes. Under the mentorship of Dr. Tafadzwa Chaunzwa, Dr. Meng uses advanced imaging, artificial intelligence, and rigorous statistics to define how the thymus—often overlooked in adult radiation planning—plays a critical role in maintaining immune surveillance against cancer.
Ross Weber, MD, PhD
Ross Weber, MD, PhD, is a Resident Physician and Research Fellow in the Holman Pathway, a specialized track dedicated to training the next generation of physician-scientists in radiation oncology. Dr. Weber’s work is centered at the intersection of immunology and cancer metabolism, where he seeks to understand the complex biochemical signals that allow tumors to evade the immune system. Under the mentorship of Sohail Tavazoie MD, PhD. Dr. Weber is currently investigating how Myeloid-Derived Suppressor Cells (MDSCs) reprogram the metabolic environment within tumors. By utilizing advanced CRISPR screening and genetic validation techniques, his research aims to identify novel therapeutic targets that can restore T-cell function and improve outcomes for patients with treatment-resistant cancers. Dr. Weber is committed to bridging the gap between laboratory discovery and clinical application, leveraging his background in both medicine and research to advance the field of oncology.